Toxicity of levodopa in parkinson disease therapy

Parkinson's disease is a universal progressive neurological disease, being a more common neurodegenerative disease in the population between 58 and 69 years old. It is constituted as a disease by the degeneration of the black base substance, where a dopamine is synthesized, associated to the presence of cytoplasmic molecules formed by the accumulation of proteins such as Lewy corpuscles. The choice of treatment depends on the functional deficit and response to the treatment already used. Levodopa (L-Dopa) is the most commonly used antiparkinsonian, as well as the most potent, highest cardiac standard, able to cause all symptoms. However, with the prolonged treatment and the high doses given, it is common for undesirable symptoms to appear and a drastic reduction of the window, so it is very clear to know it. Thus, this work aimed to investigate a disease that occurs in the disease during the most common degenerative disease among the elderly and one is associated with the medications in patients with Parkinson's disease, through a simple, descriptive bibliographic review of the last twenty years.This work was developed as a primordial tool for conducting a long term study.